Tedesco M, Mescia F, Mingyiao BM, Marasa M, Balani SS, Coppock G, Derebail V, Mariani LH, Mottl A, Navarro-Torres M, Rheault M, Stokes MB, Canetta P, Scolari F, Alberici F, Gharavi AG, Bomback AS; CureGN Consortium. Primary Glomerular Diseases in the Elderly: Clinical Features, Treatment Patterns, and Outcomes in the CureGN Cohort , Clin J Am Soc Nephrol: 2026
Mohandes S, Fakhreddine M, Sheng H, Al Dulaimee M, Mottl A, Scialla J, Almaani S, Luciano R, Isakova T, Bansal S, Argyropoulos C, Avasare R, Singh M, Campbell KN, Townsend R, Coppock G, Palmer M, Susztak K; TRIDENT Consortium. Percutaneous Native Kidney Biopsy Complications in Diabetic Patients in the TRIDENT Cohort , Clin J Am Soc Nephrol, 21: 2026,1376-1385
Hölscher DL, Schmitz NEJ, Niggemeier L, Pilva P, Strauch M, Tesar V, Barratt J, Roberts ISD, Coppo R, Barisoni L, Yanagita M, Alabalik U, Rule AD, Jagtap JM, Abreu ES, Seikrit C, von Stillfried S, Taal MW, Kalra PA, Floege J, Kramann R, Boor P, Bülow RD; VALIGA investigators; CureGN investigators; NURTuRE academic steering group; AI4IgAN study group. Individualised treatment effects of corticosteroids in IgA nephropathy , EBioMedicine: 2026
Dumoulin B, Levinsohn J, Klötzer KA, Li C, Mao L, Ha E, Mohandes S, Nguyen T, Paruzzo L, Hirohama D, Fang V, Bhoj VG, Parhiz H, Andrade-Silva M, Abedini A, Bergeson A, Traum D, May MJ, Kaestner KH, Ruella M, McAllister FE, Hakimi AA, Li M, Palmer M, Wherry EJ, Hunter CA, Cancro MP; TRIDENT consortium; Susztak K. Spatial atlas of diabetic kidney disease reveals a B cell-rich subgroup , Nature: 2026
Ayoub I, Coppock G, Wadhwani S, Yau T. KDOQI US Commentary on the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) , Am J Kidney Dis: 2026
Cummins TD, Mariani LH, Wilkey DW, Jortani SA, Helmuth M, Rane MJ, Merchant ML, Kamigaki Y, Theesfeld C, McCown PJ, Ju W, Dougherty JA, McRitchie S, Pathmasiri W, Kretzler M, Sumner SJ, Smoyer WE, Klein JB; Cure Glomerulonephropathy (CureGN) Consortium. Defining subgroups of pediatric nephrotic patients with urine proteomics , Sci Rep, 15: 2025,25064
Tarragón B, Han H, Navarro-Torres M, Canetta P, Wooden B, Derebail VK, Glenn D, Mottl A, Massicotte-Azarniouch D, Kerlin B, Hladunewich M, Coppock G, Rheault M, Mariani LH, Bomback A. Prophylactic anticoagulation in patients with nephrotic syndrome in the Cure Glomerulonephropathy (CureGN) cohort , Clin Kidney J, 18: 2025,sfaf104
Caliskan Y, Royal V, Troyanov S, Bonnefoy A, Merlen C, Schnitzler M, Edwards JC, Lentine KL, Laurin LP; CureGN Consortium. Clinical Significance of Immune Deposits and Complement System Activation in FSGS: Findings from the Cure Glomerulonephropathy Network Study , Kidney360, 6: 2025,1384-1393
Laurin LP, Helmuth M, Almaani S, Ayoub I, Chen DP, Villegas LA, Nast CC, Robinson BM, Derebail VK, Waldman M, Bomback AS; CureGN Consortium. Risk Factors for Disease Progression for Adults and Children With Membranous Nephropathy in the Cure Glomerulonephropathy Network (CureGN) , Kidney Int Rep, 10: 2025,1917-1928
Zanoni F, Marasa M, Carlassara L, Verbitsky M, Khan A, Wang C, Bundy JD, Canetta PA, Bomback AS, Parsa A, Feldman HI, Gharavi AG, Kiryluk K; CRIC Study Investigators and the CureGN Study. Family History in the Context of CKD , J Am Soc Nephrol, 36: 2025,1561-1571
